Akynzeo
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Netupitant;palonosetron
- Made by
- Helsinn Birex Pharmaceuticals Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Akynzeo is indicated in adults for the: Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy. Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Helsinn Birex Pharmaceuticals Ltd |
|---|---|
| Active substance | Netupitant;palonosetron |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A04AA · Digestion, stomach, diabetes and nutrition |
| Authorised on | 2015-05-27 |
| Last updated by the regulator | 2026-08-25 |
| EMA product number | EMEA/H/C/003728 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).